Navigation Links
Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence

ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics' product candidate for the prevention of C. difficile infections, was selected as a 2013 Top Project to Watch in the infectious disease area. This selection was made through Elsevier Business Intelligence's panel of independent experts who screen hundreds of compounds and weigh their potential as future products. The Company also announced that Jeffrey Riley, CEO, will present at the 2013 Therapeutic Area Partnerships Conference on Tuesday, November 19, 2013 at 4:00pm (EST) at the Hyatt Regency in Boston.


Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with conference attendees on Tuesday and Wednesday, November 19 and 20, 2013.

About Elsevier Business Intelligence and the Therapeutic Area Partnerships Conference

Elsevier Business Intelligence provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing a combination of news and information together with penetrating insight and analysis.

Organized by Elsevier Business Intelligence, the 2013 Therapeutic Area Partnerships (TAP) conference is designed to bring together biopharmaceutical industry decision makers to assess the most promising drug programs available for partnering in the following therapeutic areas: oncology, cardiovascular/metabolic diseases, neuroscience, infectious diseases, anti-inflammatory/autoimmune diseases and advanced therapies. For more information, please visit the conference website at

About Synthetic Biologics, Inc.

Synthetic Biologics (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
2. China Synthetic Resin Industry Report, 2013-2016
3. Synthetic Biologics to Report Third Quarter 2013 Financial Results
4. Atlantic Peptides, a Synthetic Peptide Manufacturer, Unveils Its New Website for Easier Navigation
5. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
6. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
7. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
8. Synthetic Biologics to Report Second Quarter 2013 Financial Results
9. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
10. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
11. Synthetic Biologics to Present at OneMedForum New York 2013
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):